BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld Asia
Home
» Taiwan’s Tairx advancing Nodal-targeting antibody in JV with U.S. firm BHI
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Taiwan’s Tairx advancing Nodal-targeting antibody in JV with U.S. firm BHI
Nov. 7, 2018
By
Elise Mak
No Comments
HONG KONG – Taiwanese drugmaker Tairx Inc. partnered with its U.S. peer, Biohealth Innovation Inc. (BHI), to set up a joint venture (JV) in the U.S. with the aim of developing what could be the first drug targeting the Nodal protein in cancer.
BioWorld Asia